stockrowZai Lab Limited Unsponsored ADR
ZLAB Healthcare Biotechnology
Zai Lab Limited Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $460.2 million, up 15.3% from fiscal 2024.
- Revenue
- −6.79%
- EPS
- −24.3%
- Free cash flow
- −95.5%
- Total debt
- +24.3%
Quarter to September 2026, against a year earlier
Follow ZLAB
Alert me
Zai Lab Limited Unsponsored ADR (ZLAB) Revenue growth
Zai Lab Limited Unsponsored ADR's revenue growth over the twelve months to 30 September 2026 was 0.02%, down 15.3 percentage points from fiscal 2025 (15.3%). Over the past ten years it has ranged from −99.0% (fiscal 2018) to 9,965.9% (fiscal 2019); the current reading is higher than 25% of that period. That is below the Biotechnology industry median of 6.26% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 15.3% | (34.26) |
| FY2024 | 49.6% | 25.56 |
| FY2023 | 24.0% | (24.98) |
| FY2022 | 49.0% | (145.76) |
| FY2021 | 194.8% | (82.27) |
| FY2020 | 277.0% | (9,688.85) |
| FY2019 | 9,965.9% | 10,064.91 |
| FY2018 | −99.0% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | −6.79% | (3.46) |
| Jun 2026 | −3.33% | 3.13 |
| Mar 2026 | −6.46% | (23.45) |
| Dec 2025 | 17.0% | 3.47 |
| 27 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| RXRX Recursion Pharmaceuticals, Inc. compare | 56.2% |
| ADMA ADMA Biologics Inc compare | 6.26% |
| ZLAB Zai Lab Limited Unsponsored ADR | 0.02% |
| NAMS NewAmsterdam Pharma Company N.V. compare | −26.4% |
| XNCR Xencor, Inc. compare | −28.6% |
| RCUS Arcus Biosciences, Inc. compare | −58.3% |
| CLDX Celldex Therapeutics, Inc. compare | −88.3% |
| PHVS Pharvaris N.V. compare | — |
| MBX MBX Biosciences, Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on ZLAB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement